Key result
Mitral valve genetics review highlights future gene therapies to non-invasively prevent or treat valvular degeneration.
Why the study?
To provide a comprehensive overview of the literature on mitral valve disease development, focusing on mitral valve prolapse from embryology to genetics.
This review highlights the genetic profile of mitral valve development and prolapse, advocating for future gene-based therapies to prevent or treat valvular degeneration non-invasively.
Answers are grounded in this paper and cite their sources.
Gene-based mitral therapies remain investigational; leaves open targeted validation of genetic mechanisms before clinical translation.
The purpose of this review is to present a comprehensive overview of the literature published up to February 2024 on the PubMed database regarding the development of mitral valve disease, with detailed reference to mitral valve prolapse, from embryology to a genetic profile. Out of the 3291 publications that deal with mitral valve embryology, 215 refer to mitral valve genetics and 83 were selected for further analysis. After reviewing these data, we advocate for the importance of a gene-based therapy that should be available soon, to prevent or treat non-invasively the valvular degeneration.
No takes yet. Share an insight, caveat, or question.
Opris et al. (2024) conducted a review in Mitral valve disease and mitral valve prolapse (n=83). Gene-based therapy was evaluated. A review of 83 publications on mitral valve genetics highlights the potential for future gene-based therapies to non-invasively prevent or treat valvular degeneration.
Synapse has enriched 10 related papers. Consider them for comparative context: